Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2010

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Roflumilast (Daxas®) has been rejected as an add on to bronchodilator treatment in severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in 1 second post-bronchodilator <50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations. The manufacturer did not present a sufficiently robust economic analysis.

Four combined oral contraceptive pills (Rigevidon®, Gedarel®, Millinette® and TriRegol®) were all accepted for use in patients where these products would provide an appropriate form of contraception. They provide an alternative to the existing preparations at a lower cost.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2010' on Email Share 'SMC Update - October 2010' on Delicious Share 'SMC Update - October 2010' on Digg Share 'SMC Update - October 2010' on Facebook Share 'SMC Update - October 2010' on Google+ Share 'SMC Update - October 2010' on reddit Share 'SMC Update - October 2010' on StumbleUpon Share 'SMC Update - October 2010' on Twitter

atomic-wealth

No Comments to “SMC Update - October 2010”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,523 spam comments.

atomic-wealth
fond-illness
summer